San Diego-primarily based cannabis corporation, Healthcare Marijuana Inc. (MMI) announced on Tuesday that their key investment corporation, AXIM Biotechnologies has filed a provisional patent application for a cannabinoid-infused chewing gum made for the therapy of migraine symptoms.
The proprietary chewing gum formula will be produced with cannabidiol ( CBD), cannabigerol (CBG), and an extract from the feverfew plant referred to as parthenolide.
The formulation is made to treat symptoms related with migraines such as headache discomfort, light sensitivity, and nausea.
“As a corporation of firsts, Healthcare Marijuana, Inc. is proud to help AXIM as it filed this patent application for the 1st-ever cannabis-primarily based gum formulated to treat the symptoms of migraines,” stated MMI CEO, Dr. Stuart Titus. “Studies have estimated that migraines have an effect on roughly 38 million folks in the U.S. and the industry presently lacks an successful organic therapy selection for these folks.”
AXIM CEO, John Huemoeller II says that the corporation plans to introduce a wide variety of therapy choices into the industry.
In April, AXIM entered into a service agreement with QPS Netherlands BV to conduct study on chewing gum infused with THC and CBD.
Clinical trials for the therapy of restless leg syndrome are planned for AXIMs MedChew RL item, and a bioequivalence study is in the operates for their MedChew gum with dronabinol to speedy-track by way of the FDA as an option to Marinol.